Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD. Whilst brain neurodegenerative processes...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of neurology Vol. 30; no. 5; pp. 1465 - 1480
Main Authors:	Leta, Valentina, Klingelhoefer, Lisa, Longardner, Katherine, Campagnolo, Marta, Levent, Hafize Çotur, Aureli, Federico, Metta, Vinod, Bhidayasiri, Roongroj, Chung‐Faye, Guy, Falup‐Pecurariu, Cristian, Stocchi, Fabrizio, Jenner, Peter, Warnecke, Tobias, Ray Chaudhuri, K.
Format:	Journal Article
Language:	English
Published:	England John Wiley & Sons, Inc 01.05.2023
Subjects:	Absorption Antiparkinson Agents - therapeutic use Constipation delayed gastric emptying diet Dysbacteriosis Dysphagia Fluctuations Gastric emptying Gastrointestinal Tract Helicobacter Infections - complications Helicobacter Infections - drug therapy Helicobacter pylori Humans Levodopa Levodopa - adverse effects Medical treatment medication microbiota Movement disorders Neurodegenerative diseases Parkinson Disease - complications Parkinson's disease Pathogenesis Pharmacokinetics Signs and symptoms Small intestine transport constipation microbiota Parkinson's disease absorption levodopa delayed gastric emptying dysphagia pharmacokinetics medication diet transport
ISSN:	1351-5101, 1468-1331, 1468-1331
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!